» Articles » PMID: 38638306

Methods for Integrating Trials and Non-experimental Data to Examine Treatment Effect Heterogeneity

Overview
Journal Stat Sci
Date 2024 Apr 19
PMID 38638306
Authors
Affiliations
Soon will be listed here.
Abstract

Estimating treatment effects conditional on observed covariates can improve the ability to tailor treatments to particular individuals. Doing so effectively requires dealing with potential confounding, and also enough data to adequately estimate effect moderation. A recent influx of work has looked into estimating treatment effect heterogeneity using data from multiple randomized controlled trials and/or observational datasets. With many new methods available for assessing treatment effect heterogeneity using multiple studies, it is important to understand which methods are best used in which setting, how the methods compare to one another, and what needs to be done to continue progress in this field. This paper reviews these methods broken down by data setting: aggregate-level data, federated learning, and individual participant-level data. We define the conditional average treatment effect and discuss differences between parametric and nonparametric estimators, and we list key assumptions, both those that are required within a single study and those that are necessary for data combination. After describing existing approaches, we compare and contrast them and reveal open areas for future research. This review demonstrates that there are many possible approaches for estimating treatment effect heterogeneity through the combination of datasets, but that there is substantial work to be done to compare these methods through case studies and simulations, extend them to different settings, and refine them to account for various challenges present in real data.

Citing Articles

Toward Precision in Critical Care Research: Methods for Observational and Interventional Studies.

Graham Linck E, Goligher E, Semler M, Churpek M Crit Care Med. 2024; 52(9):1439-1450.

PMID: 39145702 PMC: 11328956. DOI: 10.1097/CCM.0000000000006371.


Methods for Integrating Trials and Non-experimental Data to Examine Treatment Effect Heterogeneity.

Brantner C, Chang T, Nguyen T, Hong H, Stefano L, Stuart E Stat Sci. 2024; 38(4):640-654.

PMID: 38638306 PMC: 11025720. DOI: 10.1214/23-sts890.


Comparison of methods that combine multiple randomized trials to estimate heterogeneous treatment effects.

Brantner C, Nguyen T, Tang T, Zhao C, Hong H, Stuart E Stat Med. 2024; 43(7):1291-1314.

PMID: 38273647 PMC: 11086055. DOI: 10.1002/sim.9955.

References
1.
Dahabreh I, Petito L, Robertson S, Hernan M, Steingrimsson J . Toward Causally Interpretable Meta-analysis: Transporting Inferences from Multiple Randomized Trials to a New Target Population. Epidemiology. 2020; 31(3):334-344. PMC: 9066547. DOI: 10.1097/EDE.0000000000001177. View

2.
Green A, Trivedi N, Hsu J, Yu N, Bach P, Chimonas S . Despite The FDA's Five-Year Plan, Black Patients Remain Inadequately Represented In Clinical Trials For Drugs. Health Aff (Millwood). 2022; 41(3):368-374. DOI: 10.1377/hlthaff.2021.01432. View

3.
Xie F, Chan J, Ma R . Precision medicine in diabetes prevention, classification and management. J Diabetes Investig. 2018; 9(5):998-1015. PMC: 6123056. DOI: 10.1111/jdi.12830. View

4.
Debray T, Schuit E, Efthimiou O, Reitsma J, Ioannidis J, Salanti G . An overview of methods for network meta-analysis using individual participant data: when do benefits arise?. Stat Methods Med Res. 2016; 27(5):1351-1364. DOI: 10.1177/0962280216660741. View

5.
Teramukai S, Matsuyama Y, Mizuno S, Sakamoto J . Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. Jpn J Clin Oncol. 2005; 34(12):717-21. DOI: 10.1093/jjco/hyh138. View